DHR vs V: Which Is the Better Buy?

Side-by-side comparison of Danaher Corporation and Visa Inc. — fair value, conviction, valuation metrics, and QuantHub research signals. Updated 2026-06-20.
Danaher Corporation · Healthcare
$177.17
+8.9% upside to fair value
Grade B High Quality
VS
Visa Inc. · Financial Services
$327.24
+27.8% upside to fair value
Grade A High Quality
QuantHub Verdict
V has more upside to fair value (+27.8%). V trades at a lower forward P/E (28.2x). These are model outputs — not personalized investment advice. See all research →
Valuation & Fundamentals
Metric DHR V
Current Price $177.17 $327.24
Fair Value Estimate $192.90 $418.15
Upside to Fair Value +8.9% +27.8%
Market Cap $125.4B $627.3B
Forward P/E 34.1x 28.2x
EV / EBITDA 20.8x 22.6x
Price / Sales 5.1x 14.6x
Price / FCF 23.7x 29.6x
Revenue Growth YoY +3.7% +17.1%
Gross Margin 60.7% 81.3%
Operating Margin 21.0% 61.1%
Return on Equity 7.1% 58.9%
Dividend Yield 0% 0%
FCF Yield 4.22% 3.38%
Analyst Consensus Strong Buy Strong Buy
Investment Thesis
DHR — Danaher Corporation
Danaher Corporation operates in the healthcare sector, specializing in medical diagnostics and research tools through three balanced platforms: Biotechnology, Life Sciences, and Diagnostics. The company benefits from a durable competitive moat supported by the Danaher Business System, disciplined capital allocation, and a platform-centric organizational structure. Despite modest revenue growth of…
V — Visa Inc.
Visa Inc. operates a global payments network that facilitates electronic funds transfers worldwide, primarily through credit and debit cards. The company benefits from a very strong and widening moat driven by its extensive global card network and acceptance infrastructure, supported by a shareholder-friendly capital allocation policy including high buybacks and dividends. Visa's business quality…
Accumulation Zones
Metric DHR V
Zone Low $144.68 $313.61
Zone High $163.97 $355.43
In Buy Zone? No Yes
← DHR Research    V Research →    All Research